APO Research
Talk to an analyst

APO RESEARCH · REPORT

Primary Hyperoxaluria Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Primary Hyperoxaluria Drug Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchPrimary Hyperoxaluria Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Primary Hyperoxaluria Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Primary Hyperoxaluria Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Primary Hyperoxaluria Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Primary Hyperoxaluria Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Primary Hyperoxaluria Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Primary Hyperoxaluria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Primary Hyperoxaluria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Primary Hyperoxaluria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Primary Hyperoxaluria Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Primary Hyperoxaluria Drug market include OxThera AB, Intellia Therapeutics Inc, Dicerna Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc and Allena Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Primary Hyperoxaluria Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Primary Hyperoxaluria Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Primary Hyperoxaluria Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Primary Hyperoxaluria Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Primary Hyperoxaluria Drug Segment by Company

OxThera AB

Intellia Therapeutics Inc

Dicerna Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Allena Pharmaceuticals Inc

Primary Hyperoxaluria Drug Segment by Type

ALLN-230

ALN-GO1

DCR-PHXC

Others

Primary Hyperoxaluria Drug Segment by Application

Hospital

Clinic

Others

Primary Hyperoxaluria Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Primary Hyperoxaluria Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Primary Hyperoxaluria Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Primary Hyperoxaluria Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Primary Hyperoxaluria Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Hyperoxaluria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Primary Hyperoxaluria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Hyperoxaluria Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Primary Hyperoxaluria Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Primary Hyperoxaluria Drug industry.

Chapter 3: Detailed analysis of Primary Hyperoxaluria Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Primary Hyperoxaluria Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Primary Hyperoxaluria Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Primary Hyperoxaluria Drug Industry Trends Table 2. Primary Hyperoxaluria Drug Industry Drivers Table 3. Primary Hyperoxaluria Drug Industry Opportunities and Challenges Table 4. Primary Hyperoxaluria Drug Industry Restraints Table 5. Global Primary Hyperoxaluria Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Primary Hyperoxaluria Drug Revenue Share by Company (2021-2026) Table 7. Global Primary Hyperoxaluria Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Primary Hyperoxaluria Drug Sales Volume Share by Company (2021-2026) Table 9. Global Primary Hyperoxaluria Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Primary Hyperoxaluria Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Primary Hyperoxaluria Drug Key Company Manufacturing Base & Headquarters Table 12. Global Primary Hyperoxaluria Drug Company, Product Type & Application Table 13. Global Primary Hyperoxaluria Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Primary Hyperoxaluria Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ALLN-230 Table 18. Significant Companies of ALN-GO1 Table 19. Significant Companies of DCR-PHXC Table 20. Significant Companies of Others Table 21. Global Primary Hyperoxaluria Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Primary Hyperoxaluria Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Primary Hyperoxaluria Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Primary Hyperoxaluria Drug Sales Volume Share by Type (2021-2026) Table 25. Global Primary Hyperoxaluria Drug Sales Volume Share by Type (2027-2032) Table 26. Global Primary Hyperoxaluria Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Primary Hyperoxaluria Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Primary Hyperoxaluria Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Primary Hyperoxaluria Drug Sales Value Share by Type (2021-2026) Table 30. Global Primary Hyperoxaluria Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Primary Hyperoxaluria Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Primary Hyperoxaluria Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Primary Hyperoxaluria Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Primary Hyperoxaluria Drug Sales Volume Share by Application (2021-2026) Table 38. Global Primary Hyperoxaluria Drug Sales Volume Share by Application (2027-2032) Table 39. Global Primary Hyperoxaluria Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Primary Hyperoxaluria Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Primary Hyperoxaluria Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Primary Hyperoxaluria Drug Sales Value Share by Application (2021-2026) Table 43. Global Primary Hyperoxaluria Drug Sales Value Share by Application (2027-2032) Table 44. Global Primary Hyperoxaluria Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Primary Hyperoxaluria Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Primary Hyperoxaluria Drug Sales Market Share by Region (2021-2026) Table 47. Global Primary Hyperoxaluria Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Primary Hyperoxaluria Drug Sales Market Share by Region (2027-2032) Table 49. Global Primary Hyperoxaluria Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Primary Hyperoxaluria Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Primary Hyperoxaluria Drug Sales Value Share by Region (2021-2026) Table 52. Global Primary Hyperoxaluria Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Primary Hyperoxaluria Drug Sales Value Share by Region (2027-2032) Table 54. Global Primary Hyperoxaluria Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Primary Hyperoxaluria Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Primary Hyperoxaluria Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Primary Hyperoxaluria Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2026) Table 60. Global Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Primary Hyperoxaluria Drug Sales Market Share by Country (2027-2032) Table 62. Global Primary Hyperoxaluria Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Primary Hyperoxaluria Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Primary Hyperoxaluria Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Primary Hyperoxaluria Drug Sales Value Market Share by Country (2027-2032) Table 66. OxThera AB Company Information Table 67. OxThera AB Business Overview Table 68. OxThera AB Primary Hyperoxaluria Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. OxThera AB Primary Hyperoxaluria Drug Product Portfolio Table 70. OxThera AB Recent Development Table 71. Intellia Therapeutics Inc Company Information Table 72. Intellia Therapeutics Inc Business Overview Table 73. Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio Table 75. Intellia Therapeutics Inc Recent Development Table 76. Dicerna Pharmaceuticals Inc Company Information Table 77. Dicerna Pharmaceuticals Inc Business Overview Table 78. Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio Table 80. Dicerna Pharmaceuticals Inc Recent Development Table 81. Alnylam Pharmaceuticals Inc Company Information Table 82. Alnylam Pharmaceuticals Inc Business Overview Table 83. Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio Table 85. Alnylam Pharmaceuticals Inc Recent Development Table 86. Allena Pharmaceuticals Inc Company Information Table 87. Allena Pharmaceuticals Inc Business Overview Table 88. Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio Table 90. Allena Pharmaceuticals Inc Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Primary Hyperoxaluria Drug Distributors List Table 94. Primary Hyperoxaluria Drug Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Primary Hyperoxaluria Drug Product Image Figure 2. Global Primary Hyperoxaluria Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Primary Hyperoxaluria Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Primary Hyperoxaluria Drug Sales (2021-2032) & (W Units) Figure 5. Global Primary Hyperoxaluria Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Primary Hyperoxaluria Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ALLN-230 Image Figure 10. ALN-GO1 Image Figure 11. DCR-PHXC Image Figure 12. Others Image Figure 13. Global Primary Hyperoxaluria Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Primary Hyperoxaluria Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Primary Hyperoxaluria Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Primary Hyperoxaluria Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Primary Hyperoxaluria Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Primary Hyperoxaluria Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Primary Hyperoxaluria Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Primary Hyperoxaluria Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Primary Hyperoxaluria Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Primary Hyperoxaluria Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Primary Hyperoxaluria Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Primary Hyperoxaluria Drug Sales Value Share by Application (2021-2032) Figure 28. Global Primary Hyperoxaluria Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Primary Hyperoxaluria Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Primary Hyperoxaluria Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Primary Hyperoxaluria Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Primary Hyperoxaluria Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Primary Hyperoxaluria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Primary Hyperoxaluria Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Primary Hyperoxaluria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Primary Hyperoxaluria Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Primary Hyperoxaluria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Primary Hyperoxaluria Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Primary Hyperoxaluria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Primary Hyperoxaluria Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Primary Hyperoxaluria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Primary Hyperoxaluria Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Primary Hyperoxaluria Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • ALLN-230
  • ALN-GO1
  • DCR-PHXC
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • OxThera AB
  • Intellia Therapeutics Inc
  • Dicerna Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Allena Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Primary Hyperoxaluria Drug Sales Value (2021-2032)
  4. 1.2.2 Global Primary Hyperoxaluria Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Primary Hyperoxaluria Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Primary Hyperoxaluria Drug Market Dynamics
  1. 2.1 Primary Hyperoxaluria Drug Industry Trends
  2. 2.2 Primary Hyperoxaluria Drug Industry Drivers
  3. 2.3 Primary Hyperoxaluria Drug Industry Opportunities and Challenges
  4. 2.4 Primary Hyperoxaluria Drug Industry Restraints
3 Primary Hyperoxaluria Drug Market by Company
  1. 3.1 Global Primary Hyperoxaluria Drug Company Revenue Ranking in 2025
  2. 3.2 Global Primary Hyperoxaluria Drug Revenue by Company (2021-2026)
  3. 3.3 Global Primary Hyperoxaluria Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Primary Hyperoxaluria Drug Average Price by Company (2021-2026)
  5. 3.5 Global Primary Hyperoxaluria Drug Company Ranking (2024-2026)
  6. 3.6 Global Primary Hyperoxaluria Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Primary Hyperoxaluria Drug Company Product Type and Application
  8. 3.8 Global Primary Hyperoxaluria Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Primary Hyperoxaluria Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Primary Hyperoxaluria Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Primary Hyperoxaluria Drug Market by Type
  1. 4.1 Primary Hyperoxaluria Drug Type Introduction
  2. 4.1.1 ALLN-230
  3. 4.1.2 ALN-GO1
  4. 4.1.3 DCR-PHXC
  5. 4.1.4 Others
  6. 4.2 Global Primary Hyperoxaluria Drug Sales Volume by Type
  7. 4.2.1 Global Primary Hyperoxaluria Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Primary Hyperoxaluria Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Primary Hyperoxaluria Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Primary Hyperoxaluria Drug Sales Value by Type
  11. 4.3.1 Global Primary Hyperoxaluria Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Primary Hyperoxaluria Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Primary Hyperoxaluria Drug Sales Value Share by Type (2021-2032)
5 Primary Hyperoxaluria Drug Market by Application
  1. 5.1 Primary Hyperoxaluria Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Primary Hyperoxaluria Drug Sales Volume by Application
  6. 5.2.1 Global Primary Hyperoxaluria Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Primary Hyperoxaluria Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Primary Hyperoxaluria Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Primary Hyperoxaluria Drug Sales Value by Application
  10. 5.3.1 Global Primary Hyperoxaluria Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Primary Hyperoxaluria Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Primary Hyperoxaluria Drug Sales Value Share by Application (2021-2032)
6 Primary Hyperoxaluria Drug Regional Sales and Value Analysis
  1. 6.1 Global Primary Hyperoxaluria Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Primary Hyperoxaluria Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Primary Hyperoxaluria Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Primary Hyperoxaluria Drug Sales by Region (2027-2032)
  5. 6.3 Global Primary Hyperoxaluria Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Primary Hyperoxaluria Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Primary Hyperoxaluria Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Primary Hyperoxaluria Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Primary Hyperoxaluria Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Primary Hyperoxaluria Drug Sales Value (2021-2032)
  12. 6.6.2 North America Primary Hyperoxaluria Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Primary Hyperoxaluria Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Primary Hyperoxaluria Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Primary Hyperoxaluria Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Primary Hyperoxaluria Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Primary Hyperoxaluria Drug Sales Value (2021-2032)
  21. 6.9.2 South America Primary Hyperoxaluria Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Primary Hyperoxaluria Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Primary Hyperoxaluria Drug Sales Value Share by Country, 2025 VS 2032
7 Primary Hyperoxaluria Drug Country-level Sales and Value Analysis
  1. 7.1 Global Primary Hyperoxaluria Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Primary Hyperoxaluria Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Primary Hyperoxaluria Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Primary Hyperoxaluria Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Primary Hyperoxaluria Drug Sales by Country (2027-2032)
  6. 7.4 Global Primary Hyperoxaluria Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Primary Hyperoxaluria Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Primary Hyperoxaluria Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Primary Hyperoxaluria Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Primary Hyperoxaluria Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Primary Hyperoxaluria Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 OxThera AB
  2. 8.1.1 OxThera AB Company Information
  3. 8.1.2 OxThera AB Business Overview
  4. 8.1.3 OxThera AB Primary Hyperoxaluria Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 OxThera AB Primary Hyperoxaluria Drug Product Portfolio
  6. 8.1.5 OxThera AB Recent Developments
  7. 8.2 Intellia Therapeutics Inc
  8. 8.2.1 Intellia Therapeutics Inc Company Information
  9. 8.2.2 Intellia Therapeutics Inc Business Overview
  10. 8.2.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio
  12. 8.2.5 Intellia Therapeutics Inc Recent Developments
  13. 8.3 Dicerna Pharmaceuticals Inc
  14. 8.3.1 Dicerna Pharmaceuticals Inc Company Information
  15. 8.3.2 Dicerna Pharmaceuticals Inc Business Overview
  16. 8.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
  18. 8.3.5 Dicerna Pharmaceuticals Inc Recent Developments
  19. 8.4 Alnylam Pharmaceuticals Inc
  20. 8.4.1 Alnylam Pharmaceuticals Inc Company Information
  21. 8.4.2 Alnylam Pharmaceuticals Inc Business Overview
  22. 8.4.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
  24. 8.4.5 Alnylam Pharmaceuticals Inc Recent Developments
  25. 8.5 Allena Pharmaceuticals Inc
  26. 8.5.1 Allena Pharmaceuticals Inc Company Information
  27. 8.5.2 Allena Pharmaceuticals Inc Business Overview
  28. 8.5.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
  30. 8.5.5 Allena Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Primary Hyperoxaluria Drug Value Chain Analysis
  2. 9.1.1 Primary Hyperoxaluria Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Primary Hyperoxaluria Drug Sales Mode & Process
  6. 9.2 Primary Hyperoxaluria Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Primary Hyperoxaluria Drug Distributors
  9. 9.2.3 Primary Hyperoxaluria Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst